A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma
Objective to evaluate the safety and efficacy of ly011 cell injection in the treatment of advanced gastric adenocarcinoma.
Advanced Gastric Adenocarcinoma
BIOLOGICAL: LY011
Maximum tolerable dose（MTD）, MTD determination will based on the incidence of reported adverse events (including dose-limiting toxicities) and abnormal laboratory test results., 1month|Incidence of Treatment-Emergent Adverse Events [Safety], AEs according to CTCAE v 5.0., 2 years
Overall Response rate（ORR）, the proportion of patients with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, 2 years|Area under the curve from time 0 to the last time point (AUC0-t), Area under the curve from time 0 to the last time point for serum CAR-T cells, 1 years|Apparent clearance (CL), Apparent clearance for serum CAR-T cells, 1 years|Maximum concentration (Cmax), Maximum concentration for serum CAR-T cells, 1 years|Half-life (T½）, Half-life for serum CAR-T cells, 1 years|Area under the serum concentration-time curve (AUC0-inf), Area under the serum concentration-time curve for serum CAR-T cells, 1 years|Time to maximum concentration (Tmax), Time to maximum concentration for serum CAR-T cells, 1 years|Terminal elimination rate constant (λz), Terminal elimination rate constant for serum CAR-T cells, 1 years|Area under the curve above baseline of ANC [ANC_AUC(0-tlast)], Area under the curve above baseline of ANC for serum CAR-T cells, 1 years
Objective to evaluate the safety and efficacy of ly011 cell injection in the treatment of advanced gastric adenocarcinoma.